Preservation of allogeneic GVL effects in KGF-treated mice. B6D2F1 recipients were conditioned and transplanted as in Fig 1with the addition of 5,000 P815 tumor cells to the bone marrow inoculum at day 0. Recipients of TCD bone marrow or bone marrow plus T cells from allogeneic B6 donors were treated with KGF or control diluent from day -3 to +7 as described in Materials and Methods. Results are represented as Kaplan-Meier cumulative survival estimates from two similar experiments. Control diluent-treated TCD recipients (, n = 11), KGF-treated TCD recipients ( - - - , n = 6), control allogeneic BMT recipients ( – · · – , n = 28), KGF allogeneic BMT recipients (, n = 17). KGF versus control (allogeneic BMT groups), P < .0001.